In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Illumina, Inc.

http://www.illumina.com

Latest From Illumina, Inc.

Speed Bumps Ahead For IP Waiver But Will It Nudge Voluntary Licensing?

IP experts share views on a range of critical issues around the proposed US-backed patent waiver for COVID-19 vaccines. Proprietary materials once public can’t be pulled back, one cautioned, while others indicated the waiver risk may be the stick that pushes companies to toe the tech transfer line.

Intellectual Property Policy & Regulation

Speed Bumps Ahead For IP Waiver, But Will It Nudge Voluntary Licensing?

IP experts share views on a range of critical issues around the proposed US-backed patent waiver for COVID-19 vaccines. Proprietary materials once public can’t be pulled back, one cautioned, while others indicated the waiver risk may be the stick that pushes companies to toe the tech transfer line.

Coronavirus COVID-19 Vaccines

Speed Bumps Ahead For IP Waiver But Will It Nudge Voluntary Licensing?

IP experts share views on a range of critical issues around the proposed US-backed patent waiver for COVID-19 vaccines. Proprietary materials once public can’t be pulled back, one cautioned, while others indicated the waiver risk may be the stick that pushes companies to toe the tech transfer line.

Policy & Regulation Coronavirus COVID-19

US FDA’s Search For Class-Wide Vaccine Blood-Clot Effect Makes Scientific Sense, But Raises Questions

Several adenovirus vaccine developers say the products cannot be compared, potentially complicating the US FDA and CDC’s decision on ending the recommended pause in the use of Janssen’s vaccine.

Coronavirus COVID-19 Vaccines
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Services
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Nanotechnology, Chips, etc.
    • Pharmacogenetics-Pharmacogenomics
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Other Names / Subsidiaries
    • GenoLogics Life Sciences Software
    • GRAIL Inc.
    • Myraqa
    • Verinata Health
    • Illumina Ventures
UsernamePublicRestriction

Register